From theoretical synergy to clinical supra-additive toxicity

Journal of Clinical Oncology

Volumn 27, Issue 9, 2009, Pages 1359-1361

  Soria, Jean Charles ^a   Massard, Christophe ^a   Izzedine, Hassane ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; SORAFENIB; SUNITINIB; VASCULOTROPIN; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; PYRROLE DERIVATIVE; VASCULOTROPIN A;

CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MAXIMUM TOLERATED DOSE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RISK FACTOR; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; KIDNEY TUMOR; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NOTE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DRUG SYNERGISM; HUMANS; HYPERTENSION; INDOLES; KIDNEY NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PYRROLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 63049093979     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.8595     Document Type: Review

References (25)

1. Motzer RJ, Bukowski RM: Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 24:5601-5608, 2006
2. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007
3. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007
4. Escudier B, Pluzanska A, Koralewski P, et al: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, doubleblind phase III trial. Lancet 370:2103-2111, 2007
5. Rini BI, Halabi S, Rosenberg JE, et al: Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26:5422-5428, 2008
6. Ellis LM, Hicklin DJ: VEGF-targeted therapy: Mechanisms of anti-tumour activity. Nat Rev Cancer 8:579-591, 2008
7. Feldman DR, Baum MS, Ginsberg MS, et al: Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 27:1432-1439, 2009
8. Ellis LM: The role of neuropilins in cancer. Mol Cancer Ther 5:1099-1107, 2006
9. Verheul HM, Pinedo HM: Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 7:475-485, 2007
10. Sugimoto H, Hamano Y, Charytan D, et al: Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 278:12605-12608, 2003
11. Shaked Y, Bocci G, Munoz R, et al: Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose. Curr Cancer Drug Targets 5:551-559, 2005
12. Zhu X, Wu S, Dahut WL, et al: Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis. Am J Kidney Dis 49:186-193, 2007
13. Izzedine H, Rixe O, Billemont B, et al: Angiogenesis inhibitor therapies: Focus on kidney toxicity and hypertension. Am J Kidney Dis 50:203-218, 2007
14. Eremina V, Jefferson JA, Kowalewska J, et al: VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358:1129-1136, 2008
15. Garovic VD, Wagner SJ, Petrovic LM, et al: Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia. Nephrol Dial Transplant 22:1136-1143, 2007
16. Eremina V, Sood M, Haigh J, et al: Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111:707-716, 2003
17. Korgaonkar SN, Feng X, Ross MD, et al: HIV-1 upregulates VEGF in podocytes. J Am Soc Nephrol 19:877-883, 2008
18. Roncone D, Satoskar A, Nadasdy T, et al: Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. Nat Clin Pract Nephrol 3:287-293, 2007
19. Frangié C, Lefaucheur C, Medioni J, et al: Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 8:177-178, 2007
20. Kapiteijn E, Brand A, Kroep J, et al: Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol 18:1745-1747, 2007
21. Izzedine H, Brocheriou I, Deray G, et al: Thrombotic microangiopathy and anti-VEGF agents. Nephrol Dial Transplant 22:1481-1482, 2007
22. Groff JA, Kozak M, Boehmer JP, et al: Endotheliopathy: A continuum of hemolytic uremic syndrome due to mitomycin therapy. Am J Kidney Dis 29:280-284, 1997
23. Azad NS, Posadas EM, Kwitkowski VE, et al: Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 26:3709-3714, 2008
24. Cooney MM, Garcia JA, Elson P, et al: Sunitinib and bevacizumab in advanced solid tumors: A phase I trial. J Clin Oncol 26:160s, 2008 (suppl; abstr 3530)
25. Katavetin P, Katavetin P: VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 359:205-206, 2008